Real-World Study of Polatuzumab Vedotin-Based Regimen for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Chinese Cohort: Updated Results of 2-Year Follow-up

BLOOD(2023)

Cited 0|Views10
No score
Key words
Diffuse large B-cell lymphoma,refractory/relapsing,polatuzumab vedotin,real-world,study,China.
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined